US Senate panel adopts biosimilars bill with 12-year exclusivity
This article was originally published in Scrip
Executive Summary
The US Senate health (HELP) committee's approval of a biosimilars measure with 12 years of innovator exclusivity hands the biotechnology and pharmaceutical industries a significant victory in the face of stances taken by a powerful House Democrat and the Obama Administration that the data protection period should be in the single digits.